Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AEON Biopharma, Inc. (AEON) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing structured access to its regulatory and financial reporting. AEON is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) injection as a proposed BOTOX biosimilar for therapeutic indications under the FDA’s 351(k) biosimilar pathway. Its filings offer detailed insight into this development strategy, capital structure, and governance.
Key documents include Form 8-K current reports describing material events such as the Securities Purchase Agreement for a PIPE private placement, the Exchange Agreement with Daewoong Pharmaceutical to convert senior secured convertible notes into equity, a new note due 2030, and warrants, and updates on corporate presentations made available to investors. These filings explain terms of new securities, warrant structures, conversion mechanics, and conditions tied to stockholder approval and NYSE American rules.
AEON’s definitive proxy statement on Schedule 14A details proposals for a special meeting of stockholders, including approval of the PIPE financing, the Daewoong note exchange, and amendments to the company’s incentive award plan. This proxy statement outlines how these transactions relate to funding the development and potential commercialization of ABP-450 as a biosimilar to BOTOX, and describes voting procedures and board recommendations.
Periodic filings referenced in the company’s 8-Ks, such as its Form 10-K for the fiscal year ended December 31, 2024, provide broader context on risk factors, forward-looking statements, and financial reporting policies. AEON’s 8-Ks also furnish quarterly earnings press releases, which include condensed consolidated financial statements and discussions of operating expenses, research and development spending, and changes in fair value of financial instruments.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping users quickly understand complex topics like convertible note exchanges, warrant anti-dilution provisions, and biosimilar regulatory milestones. Real-time updates from EDGAR ensure that new forms—whether 8-Ks, proxy statements, or annual and quarterly reports—are available promptly. Users can also track equity-related disclosures, including inducement grants and incentive plan changes, to better understand AEON’s governance and compensation practices.
AEON Biopharma, Inc. furnished an update on its business by announcing financial results for the second quarter ended June 30, 2025. The company disclosed that these results were communicated through a press release dated August 12, 2025, which is included as Exhibit 99.1 to this Form 8-K.
The press release is treated as "furnished" rather than "filed" under the securities laws, which means it is not automatically subject to certain liability provisions and is not incorporated into other filings unless specifically referenced. No detailed financial figures are included in this report itself; those appear in the accompanying press release.